Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...165166167168169170171172173174175...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Anlyasis of Therapeutic effect and safty of PD-1 Inhibitors in Clinical treatment of Oral and Maxillofacial malignant tumors () -  Oct 14, 2020 - Abstract #SITC2020SITC_482;    
    Among the 33 patients, 5 patients had immune-related adverse reactions (15.2%), including 2 cases of skin rash, 1 case of skin capillary hyperplasia and 2 cases of other adverse reactions. Conclusions The patients with Oral malignant tumor treated with PD-1 inhibitor Camrelizumab injection combined with targeted drug apatinib or postoperative adjuvant therapy can effectively control tumor development, improve the survival of patients, and help to improve the stability of postoperative efficacy.
  • ||||||||||  edralbrutinib (TG-1701) / TG Therap
    Trial completion date, Trial primary completion date:  TG-1701-101: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies (clinicaltrials.gov) -  Oct 14, 2020   
    P1,  N=50, Recruiting, 
    Conclusions The patients with Oral malignant tumor treated with PD-1 inhibitor Camrelizumab injection combined with targeted drug apatinib or postoperative adjuvant therapy can effectively control tumor development, improve the survival of patients, and help to improve the stability of postoperative efficacy. Trial completion date: Dec 2020 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Jun 2023
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    New P2 trial:  Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Oct 11, 2020   
    P2,  N=42, Not yet recruiting, 
  • ||||||||||  pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
    [VIRTUAL] Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2-positive metastatic breast cancer: A retrospective study (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1117;    
    Legal entity responsible for the study: The authors. Funding: National Key Research and Development Program of China (ZDZX2017ZL-01), High-level Innovation Team of Nanjing Medical University (JX102GSP201727), Wu Jieping Foundation (320.6750.17006), Key Medical Talents (ZDRCA2016023), 333 Project of Jiangsu Province (BRA2017534 and BRA2015470), The collaborative innovation center for tumor individualization focuses on open topics (JX21817902/008) and Project of China key research and development program precision medicine research (2016YFC0905901).
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] A realworld clinical study of camrelizumab in the treatment of esophageal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1024;    
    The grade 3/4 treatment-related AEs were RCCEP (1.0%), hypothyroidism (1.0%) and anemia(1.0%). In real clinical applications, Camrelizumab is mostly used in patients with poor physical condition, metastatic and late stage, and most patients had front-line treatment.PD-L-1 detection is rarely performed in patients before medication, and most patients are treated with combination therapy of Camrelizumab.Camrelizumab is confirmed to be effective and safe in patients with esophageal cancer.Further analysis is needed to determine which factors are the positive factors in the treatment of Camrelizumab.
  • ||||||||||  pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
    [VIRTUAL] Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2positive metastatic breast cancer: A retrospective study (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_752;    
    For patients who benefited from lapatinib ≥ 6.0 months in 3 or later line therapy, pyrotinib could provide a clinically meaningful longer PFS. National Key Research and Development Program of China (ZDZX2017ZL-01), High-level Innovation Team of Nanjing Medical University (JX102GSP201727), Wu Jieping Foundation (320.6750.17006), Key Medical Talents (ZDRCA2016023), 333 Project of Jiangsu Province (BRA2017534 and BRA2015470), The collaborative innovation center for tumor individualization focuses on open topics (JX21817902/008) and Project of China key research and development program precision medicine research (2016YFC0905901).
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] A realworld clinical study of camrelizumab in the treatment of esophageal cancer (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_658;    
    The grade 3/4 treatment-related AEs were RCCEP (1.0%), hypothyroidism (1.0%) and anemia(1.0%). In real clinical applications, Camrelizumab is mostly used in patients with poor physical condition, metastatic and late stage, and most patients had front-line treatment.PD-L-1 detection is rarely performed in patients before medication, and most patients are treated with combination therapy of Camrelizumab.Camrelizumab is confirmed to be effective and safe in patients with esophageal cancer.Further analysis is needed to determine which factors are the positive factors in the treatment of Camrelizumab.
  • ||||||||||  pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
    [VIRTUAL] Efficacy and safety analysis of pyrotinib in lapatinib resistant HER2positive metastatic breast cancer: A retrospective study (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_377;    
    For patients who benefited from lapatinib ≥ 6.0 months in 3 or later line therapy, pyrotinib could provide a clinically meaningful longer PFS. National Key Research and Development Program of China (ZDZX2017ZL-01), High-level Innovation Team of Nanjing Medical University (JX102GSP201727), Wu Jieping Foundation (320.6750.17006), Key Medical Talents (ZDRCA2016023), 333 Project of Jiangsu Province (BRA2017534 and BRA2015470), The collaborative innovation center for tumor individualization focuses on open topics (JX21817902/008) and Project of China key research and development program precision medicine research (2016YFC0905901).
  • ||||||||||  AiTan (rivoceranib) / Elevar Therapeutics
    Biomarker, Trial completion date, Trial primary completion date:  BIOVAS: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Oct 7, 2020   
    P2,  N=30, Recruiting, 
    This result indicated that cordycepin and apatinib could be a promising drug combination against NSCLC. Trial completion date: Oct 2020 --> May 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal, IO Biomarker:  VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways. (Pubmed Central) -  Oct 7, 2020   
    Moreover, we investigated the effects of apatinib treatment and VEGFR2 knockdown on osteosarcoma as well as the relevant underlying mechanism...In this study, we presented the pro-metastatic functional mechanism of VEGFR2 in osteosarcoma. VEGFR2 inhibition exhibits antitumor effects through antiangiogenic effects and inhibition of immune escape, which possibly provides potential clinical treatment for metastatic osteosarcoma.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker:  Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy. (Pubmed Central) -  Oct 3, 2020   
    Additional checkpoint inhibitors including nivolumab, durvalumab, atezolizumab, and camrelizumab are in different stages of clinical development for the disease. Finally, an additional targeted approach being pursued involves PARP inhibitors (rucaparib and olaparib are both in Phase II) based on earlier study results.